All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV capsids-gene therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neurophth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 19, 2021
Details:
Subject to the terms of the agreement, Neurophth will make an initial cash payment to AAVnerGene to test ~100 AAV capsids. Within 6-12 months upon receiving the AAV capsids, Neurophth is responsible for completing the preclinical studies on these capsids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibodies
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Kodiak Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2020
Details:
AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large panel of antibodies against new targets designated by Kodiak.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
